| 期 |
栏目 |
标题 |
文件 |
| 卷 19, 编号 3 (2017) |
Articles |
The experience with the application of first-line chemotherapy regimen with EDP-M (etoposide + doxorubicin + cisplatin + mitotane) in patients with advanced adrenocortical carcinoma in the Russian Federation |
(Rus)
|
| 卷 22, 编号 4 (2020) |
CLINICAL ONCOLOGY |
Differentiated thyroid cancer |
(Rus)
|
| 卷 23, 编号 2 (2021) |
CLINICAL ONCOLOGY |
Prostate cancer |
(Rus)
|
| 卷 23, 编号 3 (2021) |
CLINICAL ONCOLOGY |
Malignant neoplasm of the bronchi and lung: Russian clinical guidelines |
(Rus)
|
| 卷 23, 编号 4 (2021) |
CLINICAL ONCOLOGY |
Gastric cancer: Russian clinical guidelines |
(Rus)
|
| 卷 24, 编号 2 (2022) |
CLINICAL ONCOLOGY |
Own experience in the treatment of primary refractory Hodgkin's lymphoma. Case report |
(Rus)
|
| 卷 24, 编号 3 (2022) |
CLINICAL ONCOLOGY |
Malignant neoplasm of the bronchi and lung: Russian clinical guidelines |
(Rus)
|
| 卷 24, 编号 4 (2022) |
CLINICAL ONCOLOGY |
Real-world efficacy of the first line therapy with prolgolimab in patients with metastatic melanoma: interim results of the FORA (FOrteca Real practice Assessment) observational study |
(Rus)
|
| 卷 26, 编号 1 (2024) |
Articles |
Final data on the efficacy of the FORA study (FOrteca Real practice Assessment): a multicenter prospective observational study on the real-world efficacy of prolgolimab in patients with metastatic melanoma in Russia |
(Rus)
|
| 卷 26, 编号 2 (2024) |
Articles |
Safety of Pembroria® during non-medical switching from Keytruda® in patients with advanced malignant neoplasms of various localizations: the REFLECTION real-world study |
(Rus)
|
